Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.

Surgical endoscopy - 1 Jul 2026

Naser Abdel-Rahman, Pather Keouna, Mobley Erin M, Rouhizadeh Masoud, Crisp Amy M, Cicali Emily J, Cavallari Larisa H, Sacco Jana M, Puri Ruchir

Abstract excerpt

INTRODUCTION: Gastroesophageal Reflux Disease (GERD) is treated primarily with proton pump inhibitors (PPIs), with surgery reserved for patients refractory to PPIs or with symptomatic hiatal hernias. PPI efficacy depends on metabolism by cytochrome P450 2C19 (CYP2C19) in the liver, which varies with genetic polymorphisms. Rapid (RM) and ultra-rapid (UM) metabolizers may require higher PPI doses for efficacy,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Gastroesophageal Reflux

Share to Genetic Variation

Share to Genotype

Share to Phenotype

Share to Proton Pump Inhibitors

Source

Identifiers

PMID: 42247133
DOI: 10.1007/s00464-026-12904-4

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.PMID 42247133Read ↗

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.Semantic proximity Read ↗

Prevalence of CYP2C19 phenotypes in patients undergoing a hiatal hernia repair.Semantic proximity Read ↗

High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease.Semantic proximity Read ↗

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.Semantic proximity Read ↗

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Semantic proximity Read ↗

CYP2C19 genetic polymorphisms and proton pump inhibitor therapy resistance in patients with gastrooesophageal reflux disease: a preliminary observational cohort study.Semantic proximity Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.Semantic proximity Read ↗

Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.Semantic proximity Read ↗

Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Semantic proximity Read ↗

Association of CYP2C19 Phenotype on Historical Medication Prescribing for Gastroesophageal Reflux Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.